Barbara Melosky

27PUBLICATIONS
46CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyMolecular targetsOncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|Jun 26, 2026
Fusion of Clinical and Deep Learning Features for Predicting Pembrolizumab Monotherapy Response in Advanced Non-Small Cell Lung Cancer.

|Feb 26, 2026
Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation Strategies.

Parneet K Cheema, Kirstin A Perdrizet, Randeep S Sangha

|Jan 11, 2025
Machine Learning and Computed Tomography Radiomics to Predict Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer: A Pilot Study.

Ian Janzen, Cheryl Ho, Barbara Melosky

|Jan 08, 2025
The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer.

Barbara Melosky, Rosalyn A Juergens, Shantanu Banerji

|Nov 26, 2024
Esophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and Management Recommendations Based on a Modified Delphi Process.

Anthony M Brade, Houda Bahig, Andrea Bezjak

|Jul 26, 2024
Confirmation of Recurrent Lung Cancer Following Resection Using Liquid Biopsy, a Proof-of-Concept Real-World Study.

Julia R Naso, Stephen Yip, Curtis Hughesman

Pageof 5

Frequent Collaborators

6 joint publications

Normand Blais

6 joint publications

Stephanie Snow

6 joint publications

Cheryl Ho

5 joint publications

Stephen Yip